DDInter1675 DDInter1840
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Simvastatin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) upregulates {v} (Gene) CBLB
CBLB {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) upregulates {v} (Gene) CCNA1
CCNA1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) downregulates {v} (Gene) RPP38
RPP38 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} (Compound) downregulates {v} (Gene) CCND1
CCND1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Simvastatin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Simvastatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Simvastatin (Compound) upregulates CBLB (Gene) and CBLB (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin (Compound) downregulates RPP38 (Gene) and RPP38 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin (Compound) downregulates CCND1 (Gene) and CCND1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)